Ono Collaborated with Captor Therapeutics to Develop Small Molecule Protein Degraders for the Treatment of Neurodegenerative Diseases
Shots:
- Captor to receive up front, R&D funding, and success-based milestones with a total value of ~$203.63M along with royalties based on global net sales. The companies collaborated to develop novel small molecule degrader drugs against neurodegenerative diseases
- Under the terms of the agreement, Ono to get an exclusive option rights to license the product globally for the further development and commercialization
- Captor will use its OptigradeTM TPD platform to advance degrader drug candidates towards the clinic in oncology and autoimmune diseases
Ref: Ono | Image: Ono
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
